

Lenalidomide - Teratogenicity - Questionnaire

# INITIAL AND FU POST MARKETING PREGNANCY REPORT

(For mother, child and father exposure reports)

# Table 1: GENERAL DETAILS (for Teva internal use only)

Source (multiple sele	ction is allowed	d):							
Spontaneous;	Solicited; Li	terature;	Health Authority;	Patient/Consumer;	Other				
(specify)			_						
Report version:  Initial Follow- up FU number:			Safety Database ID# (LRN/ Arisg number):	Local reference number (for internal use only):	Receiver's Name:	Date Received by Teva group (DD-MMM-YYYY):			
Table 2: REPORT	ER DETAILS	5							
Reporter Type:	onsumer / non-	Health c	are professional; $\square$ Ph	narmacist; $\square$ Physician; $\square$	Other Health care p	rofessional;			
Occupation:									
Reporter Name:			Tel. No:	Address (includes country):	Does the company have the patient's permission to contact the reporter in the future for follow-up information?				
					□YES □NO	YES NO			
Table 3: PATIENT  Who does this report  *Please complete sec	concern?			ather take the Suspect pro	duct?	IO			
Patient Initials:	Date of Birth		Age:	Gender:	Weight:	Height:			
Table 4: RELEVAN	NT PATIENT	MEDI	CAL HISTORY / L	ABS					
Chronic diseases (i.e. diabetes, hypertension, asthma, etc.)									
Other diseases/ labs:									
Tobacco smoking:		YES	YES NO; number of cigarettes per day:						
Alcohol drinking:		☐ YES ☐ NO							



Lenalidomide - Teratogenicity - Questionnaire

# INITIAL AND FU POST MARKETING PREGNANCY REPORT

(For mother, child and father exposure reports)

#### **Table 5: PARENT DETAILS**

Parent	Initials	Date of Birth (DD-MMM-YYYY)	Age	Weight	Height
Mother (please fill this section for child report only)					
Father (please fill this section for father exposure report only)					

### **Table 6: PREGNANCY INFORMATION**

Is the patient still pregnant?	Last menstrual period date	Pregnancy Outcome (multiple selection is allowed):						
Yes No	(DD-MMM-YYYY):	☐ Normal (No foetal anomaly) ☐ Live birth with fetal AEs ☐ Congenital Malformation	Spontaneous abortion Induced abortion Elective Abortion	☐ Ectopic pregnancy ☐ Foetal death (stillbirth) ☐ Other:				
Number of fetuses:	Expected delivery date (DD-MMM-	Delivery Date (DD-MMM-YYYY):	Child birth weight (kg):	Is the patient breast-feeding?  Yes No  If Yes, Start Date:; Stop Date:;				

In case of  $\underline{abnormal}$  current pregnancy outcome, please complete Table 7.

### Table 7: PREGNANCIES HISTORY INFORMATION (for past pregnancies)

Past pregnancies outcomes (number of pregnancies):
Normal ();
☐ Abortion(); Specify:
Birth defect/ Congenital abnormality; Specify:
Foetal death (stillbirth); Specify:
Other(); Specify:
$\square$ Is there Family history of birth defects / congenital $\ $ abnormalities? $\ \square$ YES $\ \square$ NO
Specify:



Lenalidomide - Teratogenicity - Questionnaire

# INITIAL AND FU POST MARKETING PREGNANCY REPORT

(For mother, child and father exposure reports)

### Table 8: ADVERSE EVENT/ SPECIAL SITUATION DETAILS DURING /AFTER PREGNANCY

Adverse Event (s):	Onset Date (DD-MMM-YYYY):	End Date (DD-MMM-YYYY):	Outcome*: (please use the legend below)	Serious?	Seriousness criteria**: (please use the legend below)	Reporter Causality***: (please specify which suspect drug the causality concerns) (please use the legend below)	
				☐ YES ☐ NO		Suspect Drug 1 Suspect Drug 2 Suspect Drug 3	
				☐ YES ☐ NO		Suspect Drug 1 Suspect Drug 2 Suspect Drug 3	
				☐ YES ☐ NO		Suspect Drug 1 Suspect Drug 2 Suspect Drug 3	
*Outcome: Recovered/ resolved =1; Recovering/Resolving =2; Not recovered/ not resolved =3; Recovered/ resolved with sequel =4; Fatal=5; Unknown =6.							
**Seriousness criteria: Death =1; Disability or permanent damage =2; Important Medical Event =3; Life threatening = 4; Congenital anomaly/Birth Defect =5; Hospitalization =6.							
***Causality: Possible =1; Not related =2; Not assessable =3; Not reported =4.							

### Table 9: SUSPECT DRUG(s) INFORMATION

Brand Name	Active Ingredient	Admin Route	Unit Dose	Frequency	Daily Dose	Start Date (DD-MMM- YYYY)	Stop Date (DD-MMM- YYYY)	Batch No.	Indication	Trimester Exposed*: (please use the legend below)	Action Taken**: (please use the legend below)
						nd =2; Third			n one trime:		,

<sup>\*\*</sup>Action Taken: Dosage maintained=1; Drug discontinued =2; Dose increased=3; Dose reduced=4; Not applicable=5; Unknown=6.



Lenalidomide - Teratogenicity - Questionnaire

# INITIAL AND FU POST MARKETING PREGNANCY REPORT

(For mother, child and father exposure reports)

Table 10: CONCOMITANT/ PAST DRUG(s) DETAILS

Brand name	Active ingredient	Dosing regimen	Start date	Stop date	Indication	Action Taken

Table 11: NAI	RRATIVE					
Table 12: LIN	KED CASES (i.	e. Child-Moth	ner, Twins, for	use by LSO)		